According to the updated data from the ARROW and LIBRETTO-001 trials, the most frequent ADRs of pralsetinib with a grade of 3 or higher were anemia (12%), hypertension (12%), and neutropenia (20%) (11), while the most common grade 3 or worse ADRs of selpercatinib were hypertension (13.2%), increased alanine aminotransferase level (9%), and increased aspartate aminotransferase level (6.3%) (12). This evidence concerns the gene GPT and hypertensive disorder.